TARS Stock: Price, Earnings History and SEC Filings
Tarsus Pharmaceuticals, Inc. (TARS) last traded at $74.85, up 0.88% on the latest session and down 4.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.43 against an analyst estimate of $-0.21, a miss of 104.8%.
$74.85 +0.88%
1 month-4.78%
52-week high$91.53
52-week low$53.89
Volume595,209
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TARS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.43 | $-0.21 | -104.76% |
| Mar 2026 | May 6, 2026 | $-0.16 | $-0.46 | +65.22% |
| Dec 2025 | Feb 23, 2026 | $-0.20 | $-0.19 | -5.26% |
| Sep 2025 | Nov 4, 2025 | $-0.30 | $-0.35 | +14.29% |
TARS beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TARS
SEC filing data is not available right now. You can search for TARS on SEC EDGAR.
TARS news
- Gilead Sciences (GILD) Q3 Earnings and Revenues Top EstimatesOct 29, 2026 · finance.yahoo.com
- Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026Oct 29, 2026 · finance.yahoo.com
- Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthOct 28, 2026 · finance.yahoo.com
- Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial OfficerOct 28, 2026 · finance.yahoo.com
- Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineOct 27, 2026 · finance.yahoo.com
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) is a US-listed public company on Nasdaq.